Yonhap news on January 20th, the South Korean Disease Control Agency said on the 20th that the government is negotiating with Novak Pharmaceutical Company (NVAX) of the United States on the purchase of 20 million copies of the coronavirus vaccine produced in South Korea first.
According to the Korean Department of Disease Control and Disease Control, SK Bioscience will sign a technology transfer agreement with Novak Pharmaceuticals and produce the batch of coronavirus vaccines at SK Bioscience’s domestic factory.
If the two sides reach an agreement, the government plans to purchase 20 million vaccines produced by SK Biosciences first.
Add the 56 million vaccines that South Korea has secured, a total of 76 million vaccines will be guaranteed by that time.
